Consequently, the blockade of CB1 has been shown to exert appetite-suppressing anti-obesity properties and improve several pathological features associated with obesity, thus making it a potential therapeutic target for obesity treatment [6,7]. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.